Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules
Status:
Completed
Trial end date:
2018-04-09
Target enrollment:
Participant gender:
Summary
This will be a single center, comparative pharmacokinetic, open-label, randomized,
multiple-dose, 1-period, 2-arm, parallel study of TNX-102 SL 5.6 mg (administered as 2 x 2.8
mg tablets) to AMRIX® (cyclobenzaprine hydrochloride [HCl] extended-release [ER] capsules),
30 mg.